In this study, we have demonstrated that ATRX deficient cells, including patient-derived high-grade glioma cell lines, are particularly sensitive to RTKi (pazopanib, nintedanib, sunitinib, sorafenib) and to a specific PDGFRi (CP-673451). This evidence concerns the gene ATRX and central nervous system cancer.